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Abstract
Background While laparoscopic sleeve gastrectomy (LSG) continues to be the most commonly performed bariatric operation, several variables influence surgeons’ practice patterns and patients’ decision-making in the type of bariatric procedure
to perform. The aim of this study was to evaluate patient factors that influence the decision between laparoscopic Roux-en-Y
gastric bypass (LRYGB) versus LSG.
Methods The Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) database was
queried for patients undergoing LSG and LRYGB between 2015 and 2017. Univariate analysis and multivariate logistic
regression were used to evaluate factors associated with performing LRYGB compared to LSG.
Results A total of 252,117 (72.3%) LSG and 96,677 (27.7%) LRYGB cases were identified. Patients undergoing LSG were
younger (44.3 ± 12.0 vs 45.2 ± 11.8 years; p < 0.01) and had a lower body mass index (BMI; 45.1 ± 7.8 vs 46.2 ± 8.1 kg/m2;
p < 0.01). Most of the patients were females (79.4%), white (73.0%), with an American Society of Anesthesiology (ASA)
class ≤ 3 (96.4%). The factors associated with undergoing LRYGB compared to LSG were diabetes mellitus, gastroesophageal
reflux disease, BMI ≥ 50 kg/m2, ASA class > 3, obstructive sleep apnea, hypertension, and hyperlipidemia. However, patients
with kidney disease, black race, chronic steroid use, age ≥ 60 years, recent smoking history, chronic obstructive pulmonary
disease, and coronary artery disease were more likely to undergo LSG.
Conclusions The decision to perform LRYGB is primarily driven by obesity-associated comorbidities and higher BMI,
whereas LSG is more likely to be performed in higher risk patients.
Keyword Bariatric surgery · Roux-en-Y gastric bypass · Sleeve gastrectomy · Procedure choice · Comorbidities · Body
mass index
In 2013, laparoscopic sleeve gastrectomy (LSG) surpassed
laparoscopic Roux-en-Y gastric bypass (LRYGB) as the
most commonly performed bariatric procedure [1]. The
proportion of LSGs performed continued to increase and
constituted 61.4% of all primary metabolic and bariatric
procedures performed in 2018 in the United States [1]. The
continued increase in LSG may be primarily related to its
superior safety profile compared to LRYGB [2, 3], as well as
comparable long-term weight loss and comorbidity remission [4–6].
Despite the adoption of LSG by most surgeons and
centers, there continues to be significant variability in the
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practice patterns of individual surgeons and a lack of standardized guidelines for procedure selection [7]. Kallies et al.
emphasized the importance of providing risks and benefits
of each procedure and the role of patient preference in the
decision-making [8]. Moreover, Opozda et al. surveyed 236
patients and demonstrated that patients had a clear procedure
preference based on their research, knowledge, and experience [9]. On the other hand, in their statewide analysis
evaluating 142 surgeons, Udelsman et al. described that
surgeon practice patterns had the strongest correlation with
procedure selection compared to patient or hospital-related
factors [7]. This may be due to the surgeon’s crucial role in
presenting and interpreting data for patients [7, 9].
Although the decision in procedure choice may be multifactorial, there continues to be a paucity of data on metabolic
factors and comorbidities that play a role in procedure choice.
As a result, though one procedure may be better suited for
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certain comorbidities and patient characteristics, this does
not always reflect the procedure which is ultimately selected.
The objective of this study was to evaluate patients’ factors
that influence the decision to perform LRYGB versus LSG
using the Metabolic and Bariatric Surgery Accreditation and
Quality Improvement Program (MBSAQIP) database.

Materials and methods
This retrospective study identified patients in the MBSAQIP database who underwent elective nonrevisional LSG
and LRYGB from January 1, 2015 to December 31, 2017 to
evaluate the factors influencing the choice between these two
procedures. The Institutional Review Board at our institution
deemed this study exempt from review. Written consent was
not obtained due to the de-identified nature of the data and
lack of patient interaction.

Data source
Data were obtained from the MBSAQIP Participant Use
File, the largest bariatric-specific database with 832 participating centers in the United States and Canada, and over
200,000 cases captured each year [10]. Specific preoperative
demographic variables, preoperative comorbidities, procedure information, and 30-day outcomes are collected by certified clinical reviewers with specific training in metabolic
bariatric surgery. Data accuracy and integrity are ensured
through regular audits.

Study population
We identified adult patients (≥ 18 years) using Current Procedural Terminology codes 43,775 for LSG and 43,644 and
43,645 for LRYGB. Only cases completed with the conventional laparoscopic approach were included, and cases
completed with the open or robotic-assisted approach were
excluded. Cases labeled as emergent or conversion/revision
were excluded.

Variables analyzed
Demographic variables including age, sex, race, body mass
index (BMI), and American Society of Anesthesiologists
(ASA) class were collected. Age was reported as a categorical variable. ASA class was represented as a binary variable
(≤ 3 and > 3). BMI was also represented as a binary variable
(< 50 kg/m2 and ≥ 50 kg/m2). Preoperative comorbidities and
laboratory values included diabetes mellitus, hypertension,
hyperlipidemia, coronary artery disease, gastroesophageal
reflux diseases (GERD), chronic kidney disease or end-stage
renal disease, deep vein thrombosis or pulmonary embolism,
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anticoagulation, chronic steroid use, smoking within 1 year,
chronic obstructive pulmonary disease, obstructive sleep
apnea (OSA), previous foregut surgery, and hematocrit.
Coronary artery disease was defined as the occurrence of
at least one of the following variables: previous percutaneous coronary intervention, history of myocardial infarction,
or previous cardiac surgery. Hematocrit was reported as a
binary variable (< 30% and ≥ 30%). The year the procedure
was performed was also reported as a separate variable.

Statistical analysis
Descriptive statistics were used to report baseline demographics, comorbidities, and laboratory values. Univariate
analysis used Pearson X2 for categorical variables and Student’s t-test for continuous variables. To determine the association between procedure performed and baseline characteristics, multivariate logistic regression modeling was used.
Variables were selected using a stepwise forward selection
with p < 0.05 used as an entry criterion. The adjusted odds
ratio (AOR) with 95% confidence intervals (95% CI) was
reported for each variable. Statistical significance was set
to p < 0.05. All analyses were conducted using IBM SPSS
version 25 (IBM Corp, Armonk, NY, USA).

Results
A total of 348,794 cases were included in the analysis:
252,117 (72.3%) LSG and 96,677 (27.7%) LRYGB. Baseline
demographics, preoperative comorbidities, and laboratory
values are shown in Table 1. Patients undergoing LSG were
younger (44.3 ± 12.0 vs 45.2 ± 11.8 years; p < 0.01) with a
lower proportion of patients ≥ 60 years old (11.2% vs 12.1%;
p < 0.01). Most of the patients were white (73.0%), females
(79.4%), with an ASA class of ≤ 3 (96.4%). The LSG group
had a lower BMI (45.1 ± 7.8 vs 46.2 ± 8.1 kg/m2; p < 0.01)
with a lower proportion of patients having a BMI ≥ 50 kg/m2
(21.5% vs 26.8%; p < 0.01). The most common comorbidities
recorded were hypertension (48.7%), OSA (38.2%), GERD
(30.6%), diabetes mellitus (26.4%), and hyperlipidemia
(24.1%). Hypertension, hyperlipidemia, coronary artery disease, GERD, deep vein thrombosis or pulmonary embolism,
preoperative anticoagulation, chronic obstructive pulmonary
disease, OSA, and previous foregut surgery were higher with
LRYGB. On the other hand, chronic steroid use, smoking
within the last year, and hematocrit ≤ 30% were higher in the
LSG group. There was an incremental increase in the percentage of LSG performed through the years reported (69.7%
in 2015; 72.7% in 2016; 74.0% in 2017).
Table 2 and Fig. 1 represent the results of the multivariate logistic regression analysis. The AOR represents
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Table 1  Baseline patient characteristics for laparoscopic sleeve gastrectomy and laparoscopic Roux-en-Y gastric bypass
LSG (n = 252,117)
Age, years
18–29
30–39
40–49
50–59
≥ 60
Sex
Female
Male
Race
White
Black
Other/Not reported
American Society of Anesthesiologists class
≤3
>3
Body mass index ≥ 50 kg/m2
Diabetes mellitus
Insulin dependent
Noninsulin dependent
Hypertension
Hyperlipidemia
Coronary artery disease
Gastroesophageal reflux disease
Chronic kidney disease or end-stage renal
disease
Deep vein thrombosis or pulmonary embolism
Anticoagulation
Chronic steroid use
Smoker within 1 year
Chronic obstructive pulmonary disease
Obstructive sleep apnea
Previous foregut surgery
Hematocrit ≤ 30%
Year of operation
2015
2016
2017

LRYGB (n = 96,677)

p-value
< 0.01

30,566 (12.1%)
65,446 (26.0%)
73,097 (29.0%)
54,663 (21.7%)
28,345 (11.2%)

10,145 (10.5%)
23,548 (24.4%)
28,231 (29.2%)
23,048 (23.8%)
11,705 (12.1%)

199,443 (79.1%)
52,674 (20.9%)

77,510 (80.2%)
19,167 (19.8%)

182,318 (72.3%)
47,720 (19.0%)
22,079 (8.8%)

72,387 (74.9%)
13,718 (14.2%)
10,572 (10.9%)

< 0.01

244,090 (96.8%)
8027 (3.2%)
54,067 (21.5%)

92,150 (95.3%)
4527 (4.7%)
25,930 (26.8%)

< 0.01

16,524 (6.6%)
41,555 (16.5%)
118,550 (47.0%)
56,193 (22.3%)
7679 (3.1%)
70,293 (27.9%)
2014 (0.8%)

13,310 (13.8%)
20,572 (21.3%)
51,152 (52.9%)
27,880 (28.8%)
3498 (3.6%)
36,434 (37.7%)
733 (0.8%)

< 0.01

5512 (2.2%)
6400 (2.5%)
4540 (1.8%)
22,523 (8.9%)
4134 (1.6%)
91,330 (36.2%)
4009 (1.6%)
1186 (0.5%)

2612 (2.7%)
2592 (2.7%)
1485 (1.5%)
8201 (8.5%)
1915 (2.0%)
41,874 (43.3%)
1632 (1.7%)
405 (0.4%)

< 0.01
0.02
< 0.01
< 0.01
< 0.01
< 0.01
< 0.01
0.04

73,985 (29.4%)
84,495 (33.5%)
93,637 (37.1%)

32,116 (33.2%)
31,705 (32.8%)
32,856 (34.0%)

< 0.01

< 0.01

< 0.01

< 0.01
< 0.01
< 0.01
< 0.01
0.22

Bold values indicate statistical significant (p < 0.05)

the odds of undergoing LRYGB for each variable using
LSG as a reference. A positive association with performing LSG compared to LRYGB was noted with older age
(≥ 60 years: AOR 0.83; 95% CI 0.80–0.86; p < 0.01),
male sex (AOR 0.79; 95% CI 0.77–0.80; p < 0.01), and
black race (AOR 0.71; 95% CI 0.69–0.72; p < 0.01). Variables associated with performing LRYGB were diabetes
mellitus, particularly insulin-requiring diabetes mellitus
(AOR 2.41; 95% CI 2.35–2.48; p < 0.01), GERD (AOR
1.47; 95% CI 1.45–4.50; p < 0.01), and BMI ≥ 50 kg/

m 2 (AOR 1.35; 95% CI 1.32–1.37; p < 0.01). Other
obesity-related comorbidities associated with performing LRYGB included OSA, hypertension, and hyperlipidemia. An ASA class > 3 was associated with performing
LRYGB compared to LSG (AOR 1.22; 95% CI 1.17–1.27;
p < 0.01). On the other hand, comorbidities more likely
to be associated with performing LSG included kidney disease (AOR 0.67; 95% CI 0.61–0.73; p < 0.01),
chronic steroid use (AOR 0.77; 95% CI 0.72–0.81;
p < 0.01), preoperative anticoagulation (AOR 0.85; 95%
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Table 2  Multivariate logistic regression model showing adjusted odds ratio for significant variables associated with undergoing laparoscopic
Roux-en-Y gastric bypass compared to laparoscopic sleeve gastrectomy

Age, years
18–29
30–39
40–49
50–59
≥ 60
Sex
Female
Male
Race
White
Black
Other/Not reported
American Society of Anesthesiologists class
≤3
>3
Body mass index ≥ 50 kg/m2
Diabetes mellitus
Insulin dependent
Noninsulin dependent
Hypertension
Hyperlipidemia
Coronary artery disease
Gastroesophageal reflux disease
Chronic kidney disease or end-stage renal disease
Deep vein thrombosis or pulmonary embolism
Anticoagulation
Chronic steroid use
Smoker within 1 year
Chronic obstructive pulmonary disease
Obstructive sleep apnea
Hematocrit ≤ 30%
Year of operation
2015
2016
2017

AOR (95% CI)┼

p-value reference

1.00
1.00 (0.98 – 1.03)
0.98 (0.95 – 1.00)
0.95 (0.92 – 0.97)
0.83 (0.80 – 0.86)

0.88
0.08
< 0.01
< 0.01

1.00
0.79 (0.77 – 0.80)

Reference
< 0.01

1.00
0.71 (0.69 – 0.72)
1.27 (1.24 – 1.30)

Reference
< 0.01
< 0.01

1.00
1.22 (1.17 – 1.27)
1.35 (1.32 – 1.37)

Reference
< 0.01
< 0.01

2.41 (2.35 – 2.48)
1.46 (1.43 – 1.49)
1.04 (1.02 – 1.06)
1.09 (1.07 – 1.11)
0.94 (0.90 – 0.98)
1.47 (1.45 – 1.50)
0.67 (0.61 – 0.73)
1.15 (1.09 – 1.21)
0.85 (0.80 – 0.89)
0.77 (0.72 – 0.81)
0.92 (0.90 – 0.95)
0.93 (0.88 – 0.98)
1.22 (1.20 – 1.24)
0.87 (0.78 – 0.98)

< 0.01
< 0.01
< 0.01
< 0.01
< 0.01
< 0.01
< 0.01
< 0.01
< 0.01
< 0.01
< 0.01
0.01
< 0.01
0.02

1.00
0.87 (0.85 – 0.88)
0.81 (0.80 – 0.83)

Reference
< 0.01
< 0.01

Bold values indicate statistical significant (p < 0.05)
AOR adjusted odds ratio, CI confidence interval
┼

AOR for laparoscopic Roux-en-Y gastric bypass compared to laparoscopic sleeve gastrectomy as reference

CI 0.80–0.89; p < 0.01), hematocrit ≤ 30% (AOR 0.87;
95% CI 0.78–0.98; p = 0.02), smoking within 1 year
(AOR 0.92; 95% CI 0.90–0.95; p < 0.01), chronic obstructive pulmonary disease (AOR 0.93; 95% CI 0.88–0.98;
p = 0.01), and coronary artery disease (AOR 0.94; 95% CI
0.90–0.98; p < 0.01). With the progression of the year of
operation, there was an incremental decrease in the AOR
of performing LRYGB compared to LSG.
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Discussion
Our analysis of this multi-institutional database suggests
that patient characteristics and comorbidities influence the
type of bariatric procedure performed. After multivariable
adjustment, obesity-related comorbidities such as diabetes
mellitus, GERD, OSA, and hyperlipidemia increase the odds
of undergoing LRYGB. The greatest association was noted
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Fig. 1  Adjusted odds ratio for significant variables associated with undergoing laparoscopic Roux-en-Y gastric bypass compared to laparoscopic
sleeve gastrectomy (reference)

with insulin-requiring diabetes mellitus. Moreover, patients
with BMI ≥ 50 kg/m2 were more likely to undergo LRYGB.
On the other hand, comorbidities that are associated with
a higher operative risk such as older age, coronary artery
disease, kidney disease, smoking on initial evaluation, and
chronic obstructive pulmonary disease were associated
with undergoing LSG. Interestingly, male sex and African
American race were more likely to undergo LSG compared
to LRYGB.
The decision underlying the selection of a particular surgical procedure is multifactorial and includes a combined
weighting of patient comorbidities, access to health care,
financial factors, health care insurance, patterns of physician referral, patient and surgeon preferences [11–13]. With
regards to the latter, outcomes after bariatric surgery are

differentially prioritized between patients and providers
highlighting the importance of shared decision-making to
achieve not only tangible post-bariatric surgery outcomes
such as weight loss but also to address patients’ concerns
and expectations [14, 15]. Rozier et al. identified three subgroups of patients based on responses in an internet-based
survey in Michigan: patients most focused on costs (costsensitive), patients most concerned with excess weight loss
and medical comorbidity remission (benefit-focused), and
patients most concerned with how the treatment works
including recovery and reversibility (procedure-focused)
[16]. Kallies et al. evaluated how patient preferences impact
the decision for LRYGB vs LSG using an electronic questionnaire and found that respondents selected LRYGB
when evidence-based risks and benefits of the procedure
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were presented. In contrast, preference was equivalent
when procedural images were shown [8]. With the strong
patient preferences noted towards LRYGB rather than LSG
in the questionnaire, the authors suggested that there are
likely other drivers for the increasing LSG trend seen in the
United States [8]. In another survey of Australian bariatric
surgery patients, Opozda et al. found that patients who had
undergone LRYGB supported their decision based on evidence and success rate [9]. In contrast, patients who had
undergone LSG quoted the most common reason being the
recommendation of the medical practitioner [9]. Bariatric
surgeons may be more inclined to offer a patient one type of
procedure over another depending on a clinical phenotype
and physiological mechanisms of the operations [7, 17].
Moreover, compared to patients, surgeons are more likely
to select procedures based on lower complication risks and
are less sensitive to out-of-pocket costs [16]. Udelsman
et al. found in their analysis that surgeon factors were more
strongly associated with the selection of procedure rather
than patient and hospital factors [7].
The efficacy of both LRYGB and LSG in weight loss and
remission of obesity-related comorbidities has been well
established [6, 18–25]. In a systematic review including
5264 patients from 14 studies with midterm (3–5 years) and
long-term follow-up (≥ 5 years), Shoar et al. showed better weight loss with LRYGB only in the long-term with no
significant difference between LSG and LRYGB for remission of diabetes mellitus, hypertension, and hyperlipidemia
[6]. On the other hand, in a meta-analysis of 62 studies
published by Li et al. LRYGB was superior to LSG with
regards to percentage excess weight loss as well as remission of hypertension and hyperlipidemia but not diabetes
mellitus or OSA [26]; this difference may be related to the
inclusion of studies with short-term follow-up in the latter
study. In an observational nonrandomized cohort study of
544 patients undergoing LSG and LRYGB, Jimenez et al.
found comparable effectiveness of both procedures on percentage total weight loss and excess weight loss at 10 years
of follow-up [27]. Moreover, there is a lack of consensus
on the efficacy of LSG compared to LRYGB in super-obese
patients (BMI ≥ 50 kg/m2). In a matched analysis of 57 LSG
and 57 LRYGB super-obese patients with a 7-year followup, Ahmed et al. showed a significantly lower weight loss
with the LSG cohort throughout the follow-up period [28].
On the other hand, Hong et al. compared 607 super-obese
patients undergoing LSG or LRYGB and showed no difference in percent excess weight loss up to 3 years of follow-up
[29]. Celio et al. found a higher proportion of resolution of
diabetes mellitus, hypertension, GERD, hyperlipidemia, and
obstructive sleep apnea at 1-year in LRYGB. Additionally,
while no differences in overall 30-day morbidity were found,
the LRYGB group had higher readmission and reoperation rates [30]. Despite the lack of clear benefit of LRYGB
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compared to LSG with regards to weight loss in super-obese
patients and remission of obesity-related comorbidities in
long-term studies, these comorbidities especially diabetes
mellitus as well as a BMI ≥ 50 kg/m2 seem to be associated
with a higher AOR of LRYGB based on our analysis. This
suggests that the notion that LRYGB is more effective with
regards to weight loss and comorbidity remission may persist among bariatric surgeons.
Although the role of LSG in the management of obesity
has been well established, there are concerns about its association with postoperative GERD [31]. The high incidence
of GERD after LSG may be due to increased intragastric
pressure and a hypotensive lower esophageal sphincter
resulting in increased esophageal acid exposure [32, 33].
On the other hand, LRYGB is considered an ideal anti-reflux
procedure for patients with morbid obesity and GERD [34].
In the Swiss Multicenter Bypass or Sleeve Study (SMBOSS), LSG significantly worsened the incidence of preexisting GERD (20% vs 2%) and increased the development
of de novo GERD (18% vs 2%) compared to LRYGB [25].
Mandeville et al. reported a 47.8% chance of developing de
novo GERD after LSG with a mean follow-up of 8.48 years
[35]. Moreover, a study of 110 patients undergoing LSG,
revealed an alarming rate of 9.1% of class D esophagitis and
17.2% of nondysplastic Barrett’s esophagus at 58 months
postoperatively [36]. Although some studies show different
results reporting that LSG may improve GERD symptoms
[37], in light of the emerging literature raising the prior concerns, LRYGB is considered the ideal bariatric operation
for patients with GERD [38]. This seems consistent with
our finding as patients with preoperative GERD had 1.47
adjusted odds of undergoing LRYGB compared to LSG.
Our analysis notes a tendency to performing LSG in older
patients, particularly ≥ 60 years of age. Although this may be
related to the surgeons’ inclination to offer the safer operation
in the higher risk surgical candidates [39], it is unclear based
on our analysis if there is another reason that can explain
this trend. Moreover, the MBSAQIP does not capture patient
characteristics beyond clinical parameters; other factors such
as insurance and socioeconomic status play an essential role
in the eligibility for bariatric surgery [40]. In one study, the
most common reason patients eligible for bariatric surgery
failed to undergo the procedure was insurance denial and
unattainable coverage prerequisites [40]. Additional factors
adversely impacting access to bariatric surgery include nonwhite race, uninsured or underinsured status, lower-income,
and male sex [41–44]. Discrepancies among these factors
may underlie the sex and racial disparities observed in this
study. Higher socioeconomic and insurance status may potentially improve patients’ chances of undergoing the procedure
they prefer rather than what is offered.
During bariatric surgical consultation with prospective patients the authors of this manuscript utilize the free
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Michigan Bariatric Surgical Collaborative “Weigh the
Odds” application on their smartphone to assist with procedure selection [45]. This application provides estimates of
weight loss, comorbidity remission, and 30-day complications for primary bariatric operations including comparison
of outcomes for different procedures which facilitates and
enhances joint decision-making by the patient and surgeon.
Furthermore, our practice incorporates the following management guidelines for procedure selection which are consistent with the findings of this paper. At our program, LSG
is considered a contraindication in patients with Barrett’s
esophagitis and a relative contraindication for severe erosive esophagitis or large hiatal hernia. On the other hand,
LRYGB is considered a contraindication or relative contraindication in patients with these characteristics: chronic steroid
use, long-term smoking history, iron deficiency anemia, and
high-risk status. Based on the results from this application
any complications, severe complications, and mortality are
typically twice as high with LRYGB as compared to LSG.
There is a distinction between an elevated risk from a
surgical standpoint and a patient comorbidity standpoint.
For instance, steroids have been associated with increased
complications after LRYGB including anastomotic stricture
and marginal ulcers [46], thereby increasing the likelihood
of selecting LSG in this patient population. Smoking cessation is required before bariatric surgery as it results in significant postoperative morbidity such as marginal ulceration
in patients undergoing LRYGB [47]. Thus, these patients
are more likely to undergo LSG. This may be driven by a
surgeon’s fear that patients with a preoperative smoking history may be at higher risk of smoking relapse. This relapse
rate is 9.6% at 1-year and 14.0% at 7-years after LRYGB
[48]. The high incidence of iron deficiency after LRYGB
may influence surgeons towards performing LSG in patients
with hematocrit ≤ 30% to avoid exacerbating their anemia
[49]. As mentioned previously, in contrast to these primarily surgical procedure-related factors, patient comorbidities
may also impact decision-making. Coronary artery disease
and chronic obstructive pulmonary disease are well-known
comorbidities for elevating the risk of surgery and anesthesia. Patients with chronic kidney disease and end-stage
renal disease may be better candidates for LSG given their
potential candidacy for renal transplantation in the future
due to the need for steroid therapy and a reduction in the
malabsorption of immunosuppressive medications as compared to LRYGB. Lastly, our analysis reveals an association
between a higher ASA class and undergoing LRYGB. This
is most likely driven by the higher likelihood of patients
with obesity-related comorbidities undergoing LRYGB as
data suggests better remission as compared to LSG [26,
30]. Furthermore, it is worth mentioning that ASA class
is often subjective and inconsistent. It is also influenced
by the severity of the comorbidities which is absent in the

database. Thus, this association may also be the result of
residual confounding.
This study is limited by its retrospective, nonrandomized
study design with the potential for misclassification and
selection bias. While the study’s retrospective and descriptive nature allow evaluating associations between clinical
variables and the procedure, it does not allow inferences
regarding causation. The available data do not provide
insight into the exact reason why a procedure was selected
over another, given a set of patient characteristics. Furthermore, there are lack of data on the severity of comorbidities
which factors into the procedure choice as well. There are
likely other factors that drive decision-making for selecting
a bariatric procedure that is not reflected in the variables
reported by the database used and is thus a source of residual
confounding. Moreover, there is no information on individual hospital systems or surgeons and their experiences and
preferences for selecting one procedure over the other. These
factors also influence the procedure choice and could not be
included in our analysis. Nonetheless, this large multi-institutional national database study offers insight into potential
factors that may influence and drive clinical decision-making
for selection of LSG vs LRYGB.
In conclusion, preoperative patient characteristics are differentially associated with undergoing LRYGB compared to
LSG. Patients with obesity-related comorbidities are more
likely to undergo LRYGB, whereas higher risk patients are
more likely to undergo LSG. Moreover, the presence of
GERD was associated with having LRYGB. Our analysis
also indicates the presence of gender and racial disparities
in the performance of these two operations.
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